The answer is yes, as identifying MODY can guide management and more specifically, further subtyping of MODY based on genotypes can lead to individualized treatment such as the use of sulfonylureas in HNF1A and HNF4A mutations (Gardner and Tai, 2012). The gene discussed is HNF1A; the disease is MODY.